UNLEASHING THE PROMISE OF T-CELL THERAPIES.
Cutting-edge science. A fresh approach.
Off-the-shelf approach
Allogeneic T-cell therapies can be readily available for rapid delivery within days.
Scalable manufacturing
Efficient, robust process with the ability to produce over a thousand doses from one healthy donor.
Highly versatile platform
Potential application for a wide range of disease-causing viral and non-viral targets.
We’re developing a pipeline of firsts.
Our investigational T-cell therapies target difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. We’re the first company ever to receive an approval for an allogeneic T-cell immunotherapy.
In the News
-
September 3, 2024
Atara Biotherapeutics Announces $36 Million Registered Direct Offering READ MORE -
August 12, 2024
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update READ MORE -
July 17, 2024
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease READ MORE
Dig deeper.
Explore patient stories, our clinical studies, or visit our investor hub for more information.